I don’t think the DOJ cares whether leronlimab w
Post# of 154804
(Total Views: 616)
Posted On: 12/23/2022 2:28:57 PM
I don’t think the DOJ cares whether leronlimab works or not, they are just looking at what the FDA said, what Nader knew and what he said publicly to investors. Nader traded options with info about the status that we were told a different story about. That is what the DOJ cares about.
I am sure Nader and Kaz will turn on each other and the sequence of events and emails will give a lot of background to how this happened. Could be Nader got a huge bill from Samsung and then excersized his options and Cytodyn paid the bill with the proceeds, explaining his trade. Could be the communication between the FDA was with Kaz and then translated to Nader and Nader really did not know what was really going on. Could be Amarex was put into a very unrealistic deal by Nader and the BLA was doomed from the start. Could be that Nader instructed Amarex to cut a few corners during the trial to speed thing up, etc..
Also, the arbitration is really a separate deal, it is based on Cytodyn being denied access to our data from Amarex. I am going to guess the arbitrator will want to focus only on that and not get into the DOJ trial issues at all.
A lot will come out and hopefully we can just be angry at the waste of time and money these two created. But while this is going on we now have a company that has virtually no ties to any of it anymore
I am sure Nader and Kaz will turn on each other and the sequence of events and emails will give a lot of background to how this happened. Could be Nader got a huge bill from Samsung and then excersized his options and Cytodyn paid the bill with the proceeds, explaining his trade. Could be the communication between the FDA was with Kaz and then translated to Nader and Nader really did not know what was really going on. Could be Amarex was put into a very unrealistic deal by Nader and the BLA was doomed from the start. Could be that Nader instructed Amarex to cut a few corners during the trial to speed thing up, etc..
Also, the arbitration is really a separate deal, it is based on Cytodyn being denied access to our data from Amarex. I am going to guess the arbitrator will want to focus only on that and not get into the DOJ trial issues at all.
A lot will come out and hopefully we can just be angry at the waste of time and money these two created. But while this is going on we now have a company that has virtually no ties to any of it anymore
(8)
(0)